Skip to content

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05677048
Enrollment
205
Registered
2023-01-10
Start date
2023-04-14
Completion date
2027-10-31
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Colon Cancer, Endometrial Cancer, Gynecologic Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Ovary Cancer, Pancreatic Cancer, Uterus Cancer

Brief summary

This is a community-based study requiring participant-self-enrollment, that can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome. The two main factors in this study are the IGNITE-TX intervention (website and navigator) and the free genetic counseling and testing. The IGNITE-TX Intervention is an innovative multi-modal intervention, with two components: a) interactive web "IGNITE-TX Hub" and b) genetic family navigators.

Detailed description

Primary Objectives: The primary objectives of this study are to assess the study feasibility by estimating: 1. The enrollment of probands and (ARRs) at-risk relatives over a 6-month period 2. The response rate to baseline and follow-up surveys by probands 3. The response rate to baseline and follow-up surveys by (ARRs) at-risk relatives Secondary Objectives: The secondary objectives of this study are to: 1. Measure (ARR) at-risk relatives completion of (CGT) cascade genetic testing among different study arms. 2. Measure the proportion of enrolled (ARRs) at-risk relatives who make an informed decision about (CGT) cascade genetic testing. 3. Measure the (ARR) at-risk relatives readiness for (CGT) cascade genetic testing 4. Measure proband and (ARR) at-risk relatives change in genetics knowledge 5. Measure proband readiness to communicate results of genetic testing with (ARR) at-risk relatives Secondary objectives in this feasibility study will be primary objectives in a larger study. This feasibility study is not powered to assess these objectives. Including them in this feasibility study will allow for assessment of our measurement tools (surveys from primary objectives) and offer insight into how the intervention may impact cascade genetic testing when implemented on a larger scale Exploratory Objectives: The exploratory objectives in this study are to estimate: 1. The average website traffic of the IGNITE-TX "Hub" and module completion 2. The average utilization of family genetic navigators by participants 3. Estimate the intra-familial correlation (IFC) for (ARR) at-risk relatives completion of (CGT) cascade genetic testing 4. Assess satisfaction with IGNITE-TX website modules and genetic navigator The exploratory objectives will allow for further evaluation of the IGNITE-TX website modules and navigator and understand how families with multiple (ARR)at-risk relatives respond to the intervention.

Interventions

BEHAVIORALFree genetic testing and counseling group

Option to access no-cost telegenetic counseling and genetic testing

BEHAVIORALIGNITE-TX Group

Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator

BEHAVIORALIGNITE-TX and free genetic testing and counseling group

Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Probands Inclusion Criteria: 1. 18 years of age or older 2. Speaks and/or reads English or Spanish 3. Has known deleterious/pathogenic mutation or suspected deleterious/pathogenic variant in BRCA1 or BRCA2 (HBOC) or MLH1, MSH2, MSH6, PMS2, or EPCAM (LS) 4. Has access to the internet or phone and can send and receive email and/or text messages at a US telephone number 5. Has at least one at-risk relative who meets inclusion criteria for first-degree relative

Exclusion criteria

1. Has no at-risk relatives meeting inclusion criteria 2. Has negative germline genetic testing or only variant of uncertain significance 3. Unwilling or unable to provide consent 4.2. AT-RISK RELATIVES (ARR) Inclusion Criteria: 1. 18 years of age or older 2. Speaks and reads English or Spanish 3. Resides in the United States 4. Can provide proof of deleterious/suspected deleterious HBOC or LS variant present in a first degree relative (biological mother or father, biological child, or full sibling) 5. Has access to internet or phone and can send and receive email and/or text messages at a US telephone number

Design outcomes

Primary

MeasureTime frame
Measure enrollment of probands and at-risk relatives over a 6-month periodUp to 6 months
Measure response rate to baseline and follow-up surveys by probands and at-risk relativesUp to 6 months

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJose Rauh-Hain, MD,MPH

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026